12 Week Open, Non-Comparative Switch Study Of Oral Ziprazidone In Previously Treated Schizophrenic Patients
Status:
Terminated
Trial end date:
2005-02-01
Target enrollment:
Participant gender:
Summary
There has been evidence that ziprasidone is efficacious in decreasing the magnitude of both
positive and negative symptoms of schizophrenia, and also effective in the treatment of
depressive symptoms. It shows good tolerance with low incidence of extrapyramidal side
effects and does not significantly influence body weight. As it has been shown that
ziprasidone is efficacious and safe in patients who have been pretreated with other
antipsychotic that has to be withdrawn either due to the side effects or not satisfied
efficacy. The purpose of the study was to provide further evidence for the efficacy and
safety of patients with schizophrenia and allow for psychiatrists in Hungary to gain
experience with the drug before wide commercial availability.
Phase:
Phase 4
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.